| Code: MTA10301 | Publication Date: Oct 2025 |
For detailed forecasts, data tables, and competitive benchmarking,
Explore the full Global Pharmaceutical CDMO Market.
The main drivers of this growth are the rising outsourcing of drug development and manufacturing services, increasing complexity of therapeutic pipelines requiring specialist contract partners, and the expanding need for capacity and expertise in biologics, small-molecules and formulation manufacturing.
Trends in the Pharmaceutical CDMO Market include an increase in demand for one-stop contract development and manufacturing organisations (CDMO) with workflows that include API, formulation and fill/finish. Providers are in the process of expanding capacity in biologics, cell & gene therapies and advanced dosage forms. In addition, lean manufacturing, digitalised operations, and flexible modular facilities are gaining momentum while companies partner and invest in capacity to accommodate increasing demand for contract development and manufacturing capabilities.
Developments in the Pharmaceutical CDMO Market include increased capital investment in dedicated facilities for cell, gene and viral vector manufacturing, as well as expansions of sterile injectables and high-potency APIs. Service providers are launching integrated platforms and strategic partnerships to provide turnkey solutions that start at early-phased development and progress through to commercial manufacturing. Additionally, under global supply-chain diversification and regulatory pressure, CDMOs are exploring multi-region footprints and innovations in digital manufacturing.
Some of the leading companies include: